Default company panoramic image

Euclises Pharmaceuticals, Inc.

Euclises exploits the well validated cancer target COX-2 with novel inhibitors that dramatically improve safety & anti-cancer efficacy.

  • Stage Product In Development
  • Industry Biotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Founded October 2011
  • Employees 4

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.